3D printed matrix solid forms : can the drug solubility and dose customisation affect their controlled release behaviour?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/254526 |
Resumo: | The use of 3D printing in pharmaceutics has grown over the last years, along with the number of studies on the impact of the composition of these formulations on their pharmaceutical and biopharmaceutical properties. Recently, we reported the combined effect of the infill percentage and the presence of a pore former on the drug release behaviour of 3D printed matrix solid forms prepared by fused deposition modelling. However, there are some open questions about the effect of the drug solubility and the size of these dosage forms on their controlled release properties. Therefore, we produced poly(Ɛ-caprolactone) filaments containing different soluble forms of dexamethasone (free acid, DEX; acetate ester, DEX-A; and phosphate salt, DEX-P), which showed suitable mechanical properties and printability. 3D printed solid forms were produced in two different sizes. The formulations composed of DEX-P released about 50% of drug after 10 h, while those containing DEX or DEX-A released about 9%. The drug release profiles from the 3D printed forms containing the same drug form but with different sizes were almost completely overlapped. Therefore, these 3D printed matrix solid forms can have their drug content customised by adjusting their size, without changing their controlled release behaviour. |
id |
UFRGS-2_a5dabe7c4ff5026dcf3d822ebca1bd1d |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/254526 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Santos, Juliana dosBalbinot, Gabriela de SouzaBuchner, SilvioCollares, Fabrício MezzomoWindbergs, MaikeDeon, MoniqueBeck, Ruy Carlos Ruver2023-02-08T05:04:07Z20232590-1567http://hdl.handle.net/10183/254526001160802The use of 3D printing in pharmaceutics has grown over the last years, along with the number of studies on the impact of the composition of these formulations on their pharmaceutical and biopharmaceutical properties. Recently, we reported the combined effect of the infill percentage and the presence of a pore former on the drug release behaviour of 3D printed matrix solid forms prepared by fused deposition modelling. However, there are some open questions about the effect of the drug solubility and the size of these dosage forms on their controlled release properties. Therefore, we produced poly(Ɛ-caprolactone) filaments containing different soluble forms of dexamethasone (free acid, DEX; acetate ester, DEX-A; and phosphate salt, DEX-P), which showed suitable mechanical properties and printability. 3D printed solid forms were produced in two different sizes. The formulations composed of DEX-P released about 50% of drug after 10 h, while those containing DEX or DEX-A released about 9%. The drug release profiles from the 3D printed forms containing the same drug form but with different sizes were almost completely overlapped. Therefore, these 3D printed matrix solid forms can have their drug content customised by adjusting their size, without changing their controlled release behaviour.application/pdfengInternational journal of pharmaceutics: X. Amsterdam. Vol. 5 (Dec. 2023), 100153, 9 p.Impressão tridimensionalProdutos farmacêuticos3D printingAdditive manufacturingGlucocorticoidHot melt extrusionImplantsPolyesterPrintlet3D printed matrix solid forms : can the drug solubility and dose customisation affect their controlled release behaviour?Estrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001160802.pdf.txt001160802.pdf.txtExtracted Texttext/plain52541http://www.lume.ufrgs.br/bitstream/10183/254526/2/001160802.pdf.txt9a7717c842f6aaef5dba8bfa091c10f7MD52ORIGINAL001160802.pdfTexto completo (inglês)application/pdf5338346http://www.lume.ufrgs.br/bitstream/10183/254526/1/001160802.pdf5716f53aba0ed6b568e8579012a76959MD5110183/2545262023-06-03 03:38:13.323635oai:www.lume.ufrgs.br:10183/254526Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-06-03T06:38:13Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
3D printed matrix solid forms : can the drug solubility and dose customisation affect their controlled release behaviour? |
title |
3D printed matrix solid forms : can the drug solubility and dose customisation affect their controlled release behaviour? |
spellingShingle |
3D printed matrix solid forms : can the drug solubility and dose customisation affect their controlled release behaviour? Santos, Juliana dos Impressão tridimensional Produtos farmacêuticos 3D printing Additive manufacturing Glucocorticoid Hot melt extrusion Implants Polyester Printlet |
title_short |
3D printed matrix solid forms : can the drug solubility and dose customisation affect their controlled release behaviour? |
title_full |
3D printed matrix solid forms : can the drug solubility and dose customisation affect their controlled release behaviour? |
title_fullStr |
3D printed matrix solid forms : can the drug solubility and dose customisation affect their controlled release behaviour? |
title_full_unstemmed |
3D printed matrix solid forms : can the drug solubility and dose customisation affect their controlled release behaviour? |
title_sort |
3D printed matrix solid forms : can the drug solubility and dose customisation affect their controlled release behaviour? |
author |
Santos, Juliana dos |
author_facet |
Santos, Juliana dos Balbinot, Gabriela de Souza Buchner, Silvio Collares, Fabrício Mezzomo Windbergs, Maike Deon, Monique Beck, Ruy Carlos Ruver |
author_role |
author |
author2 |
Balbinot, Gabriela de Souza Buchner, Silvio Collares, Fabrício Mezzomo Windbergs, Maike Deon, Monique Beck, Ruy Carlos Ruver |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Santos, Juliana dos Balbinot, Gabriela de Souza Buchner, Silvio Collares, Fabrício Mezzomo Windbergs, Maike Deon, Monique Beck, Ruy Carlos Ruver |
dc.subject.por.fl_str_mv |
Impressão tridimensional Produtos farmacêuticos |
topic |
Impressão tridimensional Produtos farmacêuticos 3D printing Additive manufacturing Glucocorticoid Hot melt extrusion Implants Polyester Printlet |
dc.subject.eng.fl_str_mv |
3D printing Additive manufacturing Glucocorticoid Hot melt extrusion Implants Polyester Printlet |
description |
The use of 3D printing in pharmaceutics has grown over the last years, along with the number of studies on the impact of the composition of these formulations on their pharmaceutical and biopharmaceutical properties. Recently, we reported the combined effect of the infill percentage and the presence of a pore former on the drug release behaviour of 3D printed matrix solid forms prepared by fused deposition modelling. However, there are some open questions about the effect of the drug solubility and the size of these dosage forms on their controlled release properties. Therefore, we produced poly(Ɛ-caprolactone) filaments containing different soluble forms of dexamethasone (free acid, DEX; acetate ester, DEX-A; and phosphate salt, DEX-P), which showed suitable mechanical properties and printability. 3D printed solid forms were produced in two different sizes. The formulations composed of DEX-P released about 50% of drug after 10 h, while those containing DEX or DEX-A released about 9%. The drug release profiles from the 3D printed forms containing the same drug form but with different sizes were almost completely overlapped. Therefore, these 3D printed matrix solid forms can have their drug content customised by adjusting their size, without changing their controlled release behaviour. |
publishDate |
2023 |
dc.date.accessioned.fl_str_mv |
2023-02-08T05:04:07Z |
dc.date.issued.fl_str_mv |
2023 |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/254526 |
dc.identifier.issn.pt_BR.fl_str_mv |
2590-1567 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001160802 |
identifier_str_mv |
2590-1567 001160802 |
url |
http://hdl.handle.net/10183/254526 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
International journal of pharmaceutics: X. Amsterdam. Vol. 5 (Dec. 2023), 100153, 9 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/254526/2/001160802.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/254526/1/001160802.pdf |
bitstream.checksum.fl_str_mv |
9a7717c842f6aaef5dba8bfa091c10f7 5716f53aba0ed6b568e8579012a76959 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225080336809984 |